Lantheus Holdings, Inc. (LNTH) SVP Timothy G. Healey Sells 11,314 Shares
Lantheus Holdings, Inc. (NASDAQ:LNTH) SVP Timothy G. Healey sold 11,314 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $21.51, for a total value of $243,364.14. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) traded up $0.50 on Friday, hitting $22.35. The company’s stock had a trading volume of 372,039 shares, compared to its average volume of 562,572. The firm has a market capitalization of $819.51 and a PE ratio of 19.69. Lantheus Holdings, Inc. has a 12 month low of $7.95 and a 12 month high of $24.10. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96.
Lantheus Holdings (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. The company had revenue of $79.94 million for the quarter, compared to analysts’ expectations of $77.18 million. Lantheus Holdings had a negative return on equity of 46.45% and a net margin of 9.59%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.15 earnings per share. analysts predict that Lantheus Holdings, Inc. will post 1.02 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/18/lantheus-holdings-inc-lnth-svp-timothy-g-healey-sells-11314-shares.html.
A number of research firms have issued reports on LNTH. Jefferies Group LLC reissued a “buy” rating and set a $22.00 price target (up previously from $18.00) on shares of Lantheus Holdings in a research report on Wednesday, August 2nd. Zacks Investment Research downgraded Lantheus Holdings from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 9th. Credit Suisse Group boosted their price target on Lantheus Holdings from $19.00 to $23.00 and gave the company a “neutral” rating in a research report on Friday, November 3rd. Wells Fargo & Company raised Lantheus Holdings from a “market perform” rating to an “outperform” rating in a research report on Thursday, November 2nd. Finally, BidaskClub downgraded Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Lantheus Holdings presently has a consensus rating of “Buy” and a consensus price target of $24.50.
Several institutional investors and hedge funds have recently modified their holdings of LNTH. State of Alaska Department of Revenue acquired a new position in shares of Lantheus Holdings during the second quarter worth about $102,000. Municipal Employees Retirement System of Michigan acquired a new position in shares of Lantheus Holdings during the second quarter worth about $107,000. LS Investment Advisors LLC acquired a new position in shares of Lantheus Holdings during the second quarter worth about $112,000. Quantbot Technologies LP acquired a new position in shares of Lantheus Holdings during the second quarter worth about $117,000. Finally, Sei Investments Co. lifted its stake in shares of Lantheus Holdings by 189.6% during the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 5,126 shares in the last quarter. Institutional investors own 87.55% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.